
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed's financial performance indicates a robust outlook, highlighted by an 80 basis point year-over-year increase in operating margin primarily driven by a 230 basis point rise in gross margin, supported by pricing strategies, manufacturing efficiencies, and lower component costs. The company's Americas respiratory sales reached $749 million, reflecting a 12% growth, while the overall respiratory sales in the rest of the world increased by 8%. Furthermore, the anticipated acceleration in wearables, with a significant majority of practitioners expecting an increase in CPAP patients, suggests a favorable future demand landscape for ResMed's products, reinforcing its market position.
Bears say
ResMed's gross margin remained flat sequentially, raising concerns about its financial health amid increasing competitive pressures. The company's organic revenue growth decelerated from 11% in F1Q25 to 10% in F2Q25, with projections suggesting a potential slowdown below 5% in the future due to expected market share losses and headwinds from GLP-1 weight loss drugs. Additionally, risks from Philips' re-entry into the flow generator market and weaker-than-expected margins present significant challenges that could further impact ResMed's earnings and market position.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares